535 related articles for article (PubMed ID: 17920755)
21. Cytogenetics, JAK2 and MPL mutations in polycythemia vera, primary myelofibrosis and essential thrombocythemia.
Dos Santos LC; Ribeiro JC; Silva NP; Cerutti J; da Silva MR; Chauffaille Mde L
Rev Bras Hematol Hemoter; 2011; 33(6):417-24. PubMed ID: 23049357
[TBL] [Abstract][Full Text] [Related]
22. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178
[TBL] [Abstract][Full Text] [Related]
23. JAK2 V617F and MPL W515L/K mutations in Korean patients with essential thrombocythemia.
Kim HJ; Jang JH; Yoo EH; Kim HJ; Ki CS; Kim JW; Kim SH
Korean J Lab Med; 2010 Oct; 30(5):474-6. PubMed ID: 20890078
[TBL] [Abstract][Full Text] [Related]
24. Polycythemia vera: scientific advances and current practice.
Tefferi A; Spivak JL
Semin Hematol; 2005 Oct; 42(4):206-20. PubMed ID: 16210034
[TBL] [Abstract][Full Text] [Related]
25. Application of PRV-1 mRNA expression level and JAK2V617F mutation for the differentiating between polycytemia vera and secondary erythrocytosis and assessment of treatment by interferon or hydroxyurea.
Tutaeva V; Misurin AV; Michiels JJ; Rozenberg JM; Sokolova MA; Ivanova VL; Kolosheinova TI; Manakova TE; Levina AA; Semenova EA; Khoroshko ND
Hematology; 2007 Dec; 12(6):473-9. PubMed ID: 17852451
[TBL] [Abstract][Full Text] [Related]
26. Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes.
Stein BL; Williams DM; O'Keefe C; Rogers O; Ingersoll RG; Spivak JL; Verma A; Maciejewski JP; McDevitt MA; Moliterno AR
Haematologica; 2011 Oct; 96(10):1462-9. PubMed ID: 21712540
[TBL] [Abstract][Full Text] [Related]
27. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
Vytrva N; Stacher E; Regitnig P; Zinke-Cerwenka W; Hojas S; Hubmann E; Porwit A; Bjorkholm M; Hoefler G; Beham-Schmid C
Arch Pathol Lab Med; 2014 Sep; 138(9):1203-9. PubMed ID: 25171702
[TBL] [Abstract][Full Text] [Related]
28. Prevalence of the frequency of JAK2 (V617F) mutation in different myeloproliferative disorders in Egyptian patients.
Ebid GT; Ghareeb M; Salaheldin O; Kamel MM
Int J Clin Exp Pathol; 2015; 8(9):11555-9. PubMed ID: 26617890
[TBL] [Abstract][Full Text] [Related]
29. Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations.
Passamonti F; Elena C; Schnittger S; Skoda RC; Green AR; Girodon F; Kiladjian JJ; McMullin MF; Ruggeri M; Besses C; Vannucchi AM; Lippert E; Gisslinger H; Rumi E; Lehmann T; Ortmann CA; Pietra D; Pascutto C; Haferlach T; Cazzola M
Blood; 2011 Mar; 117(10):2813-6. PubMed ID: 21224469
[TBL] [Abstract][Full Text] [Related]
30. Low
Makarik TV; Abdullaev AO; Nikulina EE; Treglazova SA; Stepanova EE; Subortseva IN; Kovrigina AM; Melikyan AL; Kulikov SM; Sudarikov AB
Genes (Basel); 2021 Apr; 12(4):. PubMed ID: 33921387
[No Abstract] [Full Text] [Related]
31. Familial chronic myeloproliferative disorders: the state of the art.
Rumi E
Hematol Oncol; 2008 Sep; 26(3):131-8. PubMed ID: 18484677
[TBL] [Abstract][Full Text] [Related]
32. JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science.
Kilpivaara O; Levine RL
Leukemia; 2008 Oct; 22(10):1813-7. PubMed ID: 18754026
[TBL] [Abstract][Full Text] [Related]
33. Infrequent occurrence of MPL exon 10 mutations in polycythemia vera and post-polycythemia vera myelofibrosis.
Pardanani A; Lasho TL; Finke CM; Tefferi A
Am J Hematol; 2011 Aug; 86(8):701-2. PubMed ID: 21674576
[No Abstract] [Full Text] [Related]
34. Systematization of analytical studies of polycythemia vera, essential thrombocythemia and primary myelofibrosis, and a meta-analysis of the frequency of JAK2, CALR and MPL mutations: 2000-2018.
Mejía-Ochoa M; Acevedo Toro PA; Cardona-Arias JA
BMC Cancer; 2019 Jun; 19(1):590. PubMed ID: 31208359
[TBL] [Abstract][Full Text] [Related]
35. Presence of calreticulin mutations in JAK2-negative polycythemia vera.
Broséus J; Park JH; Carillo S; Hermouet S; Girodon F
Blood; 2014 Dec; 124(26):3964-6. PubMed ID: 25305205
[TBL] [Abstract][Full Text] [Related]
36. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
[TBL] [Abstract][Full Text] [Related]
37. Detection of low allele burden of JAK2 exon 12 mutations using TA-cloning in patients with erythrocytosis.
Ohyashiki JH; Hisatomi H; Shimizu S; Sugaya M; Ohyashiki K
Jpn J Clin Oncol; 2009 Aug; 39(8):509-13. PubMed ID: 19491085
[TBL] [Abstract][Full Text] [Related]
38. Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F.
Zaleskas VM; Krause DS; Lazarides K; Patel N; Hu Y; Li S; Van Etten RA
PLoS One; 2006 Dec; 1(1):e18. PubMed ID: 17183644
[TBL] [Abstract][Full Text] [Related]
39. The JAK2 46/1 haplotype predisposes to MPL-mutated myeloproliferative neoplasms.
Jones AV; Campbell PJ; Beer PA; Schnittger S; Vannucchi AM; Zoi K; Percy MJ; McMullin MF; Scott LM; Tapper W; Silver RT; Oscier D; Harrison CN; Grallert H; Kisialiou A; Strike P; Chase AJ; Green AR; Cross NC
Blood; 2010 Jun; 115(22):4517-23. PubMed ID: 20304805
[TBL] [Abstract][Full Text] [Related]
40. JAK2 V617F mutation is rare in idiopathic erythrocytosis: a difference from polycythemia vera.
Yoshinaga K; Mori N; Wang YH; Tomita K; Shiseki M; Motoji T
Int J Hematol; 2008 Jul; 88(1):82-87. PubMed ID: 18528646
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
